Stock data
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY) reported revenue of US$84.28M and net income of -US$171.30M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$84.28M | — | -US$179.45M | -US$171.30M | — |
| 2024 | US$89.15M | — | -US$3.08M | US$8.00M | — |
| 2023 | US$0.03M | — | -US$67.52M | -US$54.37M | — |
| 2022 | US$1.32M | — | -US$35.52M | -US$34.68M | — |
| 2021 | US$5.51M | — | -US$19.45M | -US$20.24M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$33.66M | -US$62.34M | — |
| 2026-03-31 | US$22.68M | -US$60.62M | — |
| 2025-12-31 | US$28.09M | -US$41.32M | — |
| 2025-09-30 | US$32.50M | -US$51.15M | — |
| 2025-06-30 | US$15.72M | -US$44.88M | — |
| 2025-03-31 | US$7.97M | -US$33.94M | — |
| 2024-12-31 | US$86.58M | US$49.93M | — |
| 2024-09-30 | US$2.07M | -US$19.13M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.